Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06559774 · ClinicalTrials.gov registry record · NA

The Hastiin Bidziil (Strong Man) Intervention

A NA study of Substance Use, sponsored by Johns Hopkins Bloomberg School of Public Health.

Recruiting
Registry status
NA
Development phase
160
Enrollment target
2
Study locations

NCT06559774: Recruiting NA study of Substance Use, sponsored by Johns Hopkins Bloomberg School of Public Health.

NCT06559774 is a NA study of Substance Use that is actively recruiting participants, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 160 participants, below the 1,259-participant average among 88 other Substance Use trials with a reported enrollment target (87% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06559774, a NA study of Substance Use, is actively recruiting participants, sponsored by Johns Hopkins Bloomberg School of Public Health.

RECRUITING
Registry status
NA
Development phase
160 participants
Enrollment target
2
Study locations

Study Summary

The Hastiin Bidziil (Strong man) Intervention study is part of a larger project called, Community-Driven Indigenous Research, Cultural Strengths \& Leadership to Advance Equity in Substance Use Outcomes (CIRCLE) Center of Excellence. CIRCLE aims to address drug use related health problems in collaboration with diverse Indigenous communities. This study is a randomized controlled trial study to measure the effectiveness of a secondary prevention program, called Hastiin Bidziil (Strong Man), aimed at reducing substance use among Native American Indian (AI) men ages 18-26.

Primary Outcome

Number of days of substance use over the previous month measured at 8-months post baseline using Timeline Follow-Back (TLFB)

Conditions Studied

Interventions

  • BEHAVIORAL Hastiin Bidziil
  • OTHER Control condition - vehicle maintenance

Study Locations (2)

Arizona

  • Navajo Nation Center for Indigenous Health - Chinle - Chinle
  • Navajo Nation Center for Indigenous Health - Fort Defiance - Fort Defiance

Trial Details

FieldValue
Enrollment Target 160 participants
Start Date 2025-06-18
Est. Completion 2029-03
Phase NA

What NCT06559774 shows while recruiting

NCT06559774 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 1,259-participant average among 88 other Substance Use trials with a reported enrollment target (87% lower).

The record links to 1 condition, with Substance Use appearing as the primary indexed condition, and to 2 interventions - of which Hastiin Bidziil is the first listed.

NCT06559774 reports a single indexed study location in Arizona.

Frequently Asked Questions

What is clinical trial NCT06559774 about?

NCT06559774 is a clinical study titled "The Hastiin Bidziil (Strong Man) Intervention". The Hastiin Bidziil (Strong man) Intervention study is part of a larger project called, Community-Driven Indigenous Research, Cultural Strengths \& Leadership to Advance Equity in Substance Use Outcomes (CIRCLE) Center of Excellence. CIRCLE aims to address drug use related health problems in collabo...

What is the current status of trial NCT06559774?

This trial is currently recruiting. It is a NA study. The enrollment target is 160 participants. The study started on 2025-06-18. Estimated completion is 2029-03.

What conditions does trial NCT06559774 study?

This clinical trial studies the following conditions: Substance Use.

What interventions are being tested in trial NCT06559774?

The interventions under investigation include: Hastiin Bidziil (BEHAVIORAL), Control condition - vehicle maintenance (OTHER).

Who is sponsoring clinical trial NCT06559774?

This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06559774 being conducted?

This trial has 2 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Substance Use

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06559774's enrollment target sits among peer trials

160 54th of 88 higher than 35 of 88 other Substance Use trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Substance Use trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00501826 · 160 participants · Phase 2

    Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

  • NCT00932139 · 160 participants · NA

    Effect of Electro-Acupuncture on Blood Pressure

  • NCT00992901 · 160 participants · Early Phase 1

    Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

  • NCT01515527 · 160 participants · Phase 2

    Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06559774, the US trial registry maintained by the National Library of Medicine. NCT06559774 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.